No profile data available.
TAO Synergies Inc. (TAOX) is a healthcare company in the brain and nerve treatment drugs industry, based in New York, United States, with about 4 full-time employees.
It reported revenue of $299,061 for fiscal year 2025, and net income of -$29.08 million. In Q1 2026 (the quarter ended March 31, 2026) revenue was $388,774. Its market capitalization was $28.74 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
TAO Synergies Inc. owns and operates an AI token. It focuses on the pure play artificial intelligence (AI) crypto coin, TAO, the native cryptocurrency of Bittensor and a decentralized blockchain network for machine learning and AI. The company was formerly known as Synaptogenix, Inc. and changed its name to TAO Synergies Inc. in June 2025.
TAO Synergies reported $299,061 in revenue for fiscal year 2025. In Q1 2026 revenue was $388,774.
$28.74 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include Incannex Healthcare Inc. (IXHL), Quince Therapeutics, Inc. (QNCX), Mira Pharmaceuticals, Inc. (MIRA), Aytu BioPharma, Inc. (AYTU).